68Ga-NOTA-RM26 PET/CT 评估胶质瘤:一项前瞻性先导研究
该前瞻性先导研究纳入22例经手术或活检确诊的胶质瘤患者,首次评估68Ga-NOTA-RM26 PET/CT的可行性,分析SUVmax与胶质瘤级别、分类及分子改变的关系。所有患者均显示示踪剂摄取,SUVmax在级别间差异有统计学意义(P=0.047),GRPR表达与SUVmax正相关(P<0.01),P53突变者SUVmax差异有统计学意义(P=0.03)。
要点
- 22例胶质瘤患者均见68Ga-NOTA-RM26摄取,SUVmax用于分析。
- 全部胶质瘤患者中,不同级别间SUVmax差异有统计学意义(P=0.047)。
- 原发胶质瘤中,SUVmax对肿瘤分类(P=0.045)和级别(P=0.03)均有较好区分度。
核心结论
- 本研究首次将68Ga-NOTA-RM26应用于胶质瘤患者,确认了其在胶质瘤患者中的安全性和有效性。
- 68Ga-NOTA-RM26 PET/CT在肿瘤级别、分类和分子改变方面具有潜在价值。
研究设计与样本
- 前瞻性先导研究,纳入22例经手术或活检确诊为胶质瘤的患者。
- 所有患者行68Ga-NOTA-RM26 PET/CT,选择SUVmax作为分析用影像标志物。
- 分析SUVmax与胶质瘤级别、分类及分子改变的关系。
- 试验注册号ClinicalTrials.gov:NCT06412952,注册日期2024年4月26日。
主要发现
- 所有患者均表现出68Ga-NOTA-RM26摄取。
- 全部胶质瘤患者中,不同级别间SUVmax差异有统计学意义(P=0.047)。
- 原发胶质瘤中,SUVmax对肿瘤分类(P=0.045)和级别(P=0.03)均有较好区分度。
- GRPR表达水平与SUVmax呈正相关(P<0.01)。
- P53突变导致SUVmax差异有统计学意义(P=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of 68Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations. RESULTS: Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited 68Ga-NOTA-RM26 uptake. SUVmax was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUVmax had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUVmax. P53 mutations caused significant differences in SUVmax (P = 0.03). CONCLUSIONS: This study is the first application of 68Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. 68Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.
引用
- Li Y, Wang R, Chen J, et al. 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study. EJNMMI Res. 2025. PMID: 39821814. doi:10.1186/s13550-025-01198-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。